Complimentary access to the JTO and a 15% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 20.4, JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews and opinion pieces. JTO CRR, IASLC’s open access companion title, publishes a range of manuscripts from subset analyses of published trials to high-quality case reports. JTO CRR is indexed in PubMed Central.
Editor-in-Chief, JTO on 2022 Impact Factor
Alex A. Adjei, MD, PhD
"JTO’s impact factor has more than quadrupled from 5.040 in 2015 to 20.4 in 2022. This is a notable achievement since we are a sub-specialty journal dealing with only thoracic oncology. There are no other sub-specialty journals among the top 20 oncology journals. More importantly, the impact factor of other journals in thoracic oncology or surgery fell in 2022. This achievement is a testament to the exemplary work of our editorial board and our managing editor, as well as the support of IASLC—its executives, office staff, membership, and above all, our reviewers, readers, and authors. JTO will continue its emphasis on multidisciplinary research to serve the broad community working in thoracic oncology.”
JTO CRR Editor-in-Chief
Emily Stone, MBBS, PhD, FRACP
Dr. Emily Stone will officially take the reins as the Editor-in-Chief of JTO Clinical and Research Reports (JTO CRR) on January 9, 2023, as Dr. Alex Adjei steps down from the role and continues his role as the Editor-in-Chief of the Journal of Thoracic Oncology (JTO). Dr. Stone is a consultant respiratory physician and Head of Thoracic Medicine within the Department of Thoracic Medicine and Lung Transplantation at St Vincent’s Hospital Sydney. She is the founding and immediate past Chair of the St Vincent’s Hospital Lung Cancer Multidisciplinary Team and the Deputy Board Chair of the Thoracic Oncology Group of Australasia. She has been an Associate Editor for both the JTO and JTO CRR since 2016 and 2020, respectively. She also served as the Chair of the IASLC Tobacco Control Committee from 2018 to 2019. Her chief clinical and research interests are in the fields of lung cancer screening, multidisciplinary team care, and tobacco control.
We are excited for the next chapter under Dr. Stone's editorial leadership and strategic stewardship of JTO CRR. The editorial teams of JTO and JTO CRR are committed to continuing to join forces towards research excellence, impacting clinical practice and global readership. We want to express our utmost appreciation to Dr. Adjei for his leadership and vision in paving the way for JTO CRR. Please join us in welcoming Dr. Stone to the JTO CRR family.
Most-Cited Journal of Thoracic Oncology Articles in 2022
Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
JTO by the Numbers
Recent journal articles
Brief Report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma - RIOMeso
The Perceived Value of Avoiding Tissue Biopsy: Results from a Canadian Validation Study of Circulating Tumour DNA T790M Testing – Patient’s Willingness to Pay: A Brief Report
Effectiveness and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in pulmonary sarcomatoid carcinoma
The impact of on-target resistance mediated by EGFR-T790M or EGFR-C797S on EGFR exon 20 insertion mutation active tyrosine kinase inhibitors
Immune-Related Toxicity in Non-small cell Lung Cancer: Current State-of-The-Art and Emerging Clinical Challenges
BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC)
HIP1-ALK-rearranged lung cancer in a young adult with BRAF V600E mutation detected after ALK-TKI therapy: a case report
The Interplay between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy
Discover the JTO
More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 1 week to initial decision, and an average of 1.6 weeks for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.
JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.